Havedic and Myrtelle Partner to Develop Oligodendrocyte-Targeting AAVs

Havedic Pharmaceutical is excited to announce a new partnership with Myrtelle, Inc. to develop novel adeno-associated virus (AAV) capsids targeting oligodendrocytes. (link)